1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Aduhelm May Not Be Perfect, But It May Be A Start – If Patients Can Access It

Debate At CTAD Underscores Doctors’ Dilemma

 
• By Mandy Jackson

The Biogen/Eisai drug may have a disease-modifying impact on Alzheimer’s progression but the lack of published evidence is still causing prescriber reluctance and hampering reimbursement decisions.

Doctor viewing patient's brain scan on digital tablet in laboratory
Academic doctors may be able to inform initial Aduhelm treatment decisions • Source: Alamy

Neurologists at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting conceded that the mixed Phase III results for Biogen, Inc./Eisai Co., Ltd.’s Aduhelm (aducanumab) complicate decisions about whether to prescribe the drug. However, they also suggested that Aduhelm as is the first and only potentially disease-modifying therapy approved in the US for Alzheimer’s disease, ongoing debates around safety and efficacy should not prevent doctors from trying the medicine in patients with no other options.

A 9 November roundtable discussion of the US Food and Drug Administration’s accelerated approval of Aduhelm in June underscored the ongoing dilemma that prescribers face

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Ferrer Signs Deal For Prilenia’s Pridopidine In Europe

 
• By Sushmita Panda

The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.